BioPharma Dive March 3, 2025
Jonathan Gardner

A licensing deal with Denmark’s Gubra gives the immunology giant ownership of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

Dive Brief:

  • AbbVie is joining the industry’s rush to develop new obesity medicines, announcing Monday a deal with Denmark-based Gubra to license a drug that could compete with experimental therapies being developed by Novo Nordisk, Eli Lilly and Zealand Pharma.
  • Per deal terms, AbbVie will pay Gubra $350 million up front and offer up to $1.9 billion in additional payments tied to the achievement of development and sales milestones. AbbVie will assume responsibility for development and commercialization.
  • Gubra is developing a type of drug called an amylin analog that regulates appetite and...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Related Articles:
Why Walgreens Specialty Pharmacy May Be Its Most Desirable Asset
Pharma Pulse 3/3/25: Will Tariffs Affect Branded Drug Prices? Pharmacists' Role in Medical Cannabis Counseling and Patient Education & more
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
Pharma’s Role in Ensuring Patient Access to Trustworthy Health Insights
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic

Share This Article